RT @BCD_AACR: Upcoming session at #AACR24 on Drugging Transcription Factors will feature Ben Ebert talking targeted degradation of TFs. Rea…

Upcoming session at #AACR24 on Drugging Transcription Factors will feature Ben Ebert talking targeted degradation of TFs. Read his work on using Avadomide to degrade ZMYM2 fusions in hematological malignancies: https://t.co/RI31L2SSe0 @DanaFarber @AACR htt

RT @DaveGennert: Wrapping up #AACRbcd24, Ben Ebert @DanaFarber takes us through his lab's work screening for disease-associated TFs suscept…

RT @DaveGennert: Wrapping up #AACRbcd24, Ben Ebert @DanaFarber takes us through his lab's work screening for disease-associated TFs suscept…

RT @DaveGennert: Wrapping up #AACRbcd24, Ben Ebert @DanaFarber takes us through his lab's work screening for disease-associated TFs suscept…

RT @DaveGennert: Wrapping up #AACRbcd24, Ben Ebert @DanaFarber takes us through his lab's work screening for disease-associated TFs suscept…

Wrapping up #AACRbcd24, Ben Ebert @DanaFarber takes us through his lab's work screening for disease-associated TFs susceptible to Ub-ligase degradation. Check out his work in @BCD_AACR characterizing one such interaction, ZMYM2 degraded by avadomide+CRBN:

RT @BCD_AACR: If you're watching the session on targeted #ProteinDegradation at #AACR22, this study on expanding targets of thalidomide an…

RT @BCD_AACR: If you're watching the session on targeted #ProteinDegradation at #AACR22, this study on expanding targets of thalidomide an…

If you're watching the session on targeted #ProteinDegradation at #AACR22, this study on expanding targets of thalidomide analogues, might be of interest: https://t.co/NmLH31cOtD https://t.co/OOmerNdREk

RT @shahvarun28: 7. Thalidomide analogue Avadomide induces the degradation of ZMYM2 fusion oncoproteins. This study from ebert lab highligh…

7. Thalidomide analogue Avadomide induces the degradation of ZMYM2 fusion oncoproteins. This study from ebert lab highlights 1) use of IMiD deravatives in inducing neo-substrate degradation and 2) broader potential of TPD in targeting fusion proteins.https

RT @BCD_AACR: #ICYMI: Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies. https://t.co/ShOZzRLAr7 @bro…

RT @BCD_AACR: #ICYMI: Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies. https://t.co/ShOZzRLAr7 @bro…

#ICYMI: Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies. https://t.co/ShOZzRLAr7 @broadinstitute #bloodcancer #targetedtherapy https://t.co/6B0uimRUwm

#ICYMI: Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies. @broadinstitute #bloodcancer #targetedtherapy https://t.co/dcWfheGCFp https://t.co/Xz7mhTIUoa

RT @jjkiladjian: Avadomide, a potential new tool to treat patients with ZMYM2 fusion proteins like ZMYM2-FGFR1 and ZMYM2-FLT3, thanks Aline…

Ce travail ouvre des perspectives de combinaison avec les inhibiteurs spécifiques du partenaire de ZMYM2 pour éviter ou dépasser les résistances par acquisition de mutations Avadomide induces degradation of ZMYM2 fusion oncoproteins https://t.co/dfSWrfoNNM

RT @jjkiladjian: Avadomide, a potential new tool to treat patients with ZMYM2 fusion proteins like ZMYM2-FGFR1 and ZMYM2-FLT3, thanks Aline…

Thanks Jean-Jacques, and with the contribution of the @GustaveRoussy "myeloid" team: S de Botton, S Cotteret, C Marzac

Avadomide, a potential new tool to treat patients with ZMYM2 fusion proteins like ZMYM2-FGFR1 and ZMYM2-FLT3, thanks Aline Renneville for the nice collaborative work @saada_vsaada @broadinstitute @HopSaintLouis @Institut_IRSL @Univ_Paris @DanaFarber http

#ICYMI: Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies. @broadinstitute #bloodcancer #targetedtherapy https://t.co/WvEBVNyluv https://t.co/eIZMQHMRJc

From the May issue: Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies. @broadinstitute #bloodcancer #targetedtherapy https://t.co/Ow5JsuA94g https://t.co/88jhgaIfBa

RT @_TanyaBondar_: Right now: Ben Ebert's opening keynote talk #VKSHemato21 on oncoprotein degradation presents findings just published in…

RT @_TanyaBondar_: Right now: Ben Ebert's opening keynote talk #VKSHemato21 on oncoprotein degradation presents findings just published in…

Right now: Ben Ebert's opening keynote talk #VKSHemato21 on oncoprotein degradation presents findings just published in @BCD_AACR: https://t.co/FzlHW9oan3

Watching Benjamin Ebert's talk on clonal hematopoiesis at #VKSHemato21? See his recent paper: Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies. https://t.co/hiuE0CRAWn https://t.co/pOHZF4E8Wy

Just published #OnlineFirst: Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies. @broadinstitute #bloodcancer #targetedtherapy https://t.co/beU7to98MV https://t.co/gVtHq8SyWv

RT @BCD_AACR: Just published #OnlineFirst: Avadomide induces degradation of ZMYM2 fusion oncoproteins in #hematologicmalignancies. @DanaFar…

New research from Benjamin Ebert's lab identifies a new oncogenic fusion target for avadomide.

RT @BCD_AACR: Just published #OnlineFirst: Avadomide induces degradation of ZMYM2 fusion oncoproteins in #hematologicmalignancies. @DanaFar…

Just published #OnlineFirst: Avadomide induces degradation of ZMYM2 fusion oncoproteins in #hematologicmalignancies. @DanaFarberNews https://t.co/BgB8RiIMtG https://t.co/cCXDLSSu3p